Narrowband UVB vs. PUVA: Comparing Phototherapy Options

Narrowband UVB and PUVA are the two main forms of phototherapy for psoriasis, and choosing between them involves genuine trade-offs the research has actually quantified. Here's an honest comparison.

How Each Treatment Works

Narrowband UVB (NB-UVB) uses a specific, narrow wavelength of ultraviolet B light, applied directly to the skin, to slow excessive skin cell turnover. PUVA (psoralen plus UVA) combines a photosensitizing medication called psoralen — taken orally or applied directly to skin — with UVA light exposure; the psoralen makes skin more reactive to the UVA light, enhancing its therapeutic effect.

What the Comparative Trials Show

This is a genuinely well-studied head-to-head comparison, and the results are nuanced rather than a clear winner. A paired-comparison study found narrowband UVB reduced PASI scores by 84% versus 89% for PUVA — a difference that leaned toward PUVA but didn't reach statistical significance overall. However, the same study found a meaningful pattern: patients with higher baseline PASI scores (more severe disease) responded significantly better to PUVA specifically, while narrowband UVB performed comparably for milder cases.

A separate randomized study found PUVA required significantly fewer total treatment sessions to achieve clearance than narrowband UVB, though there was no significant difference in the number of days in remission afterward — suggesting PUVA may work somewhat faster, without necessarily providing more durable results.

For palmoplantar psoriasis specifically — one of the harder-to-treat presentations we've covered separately — one study found PUVA modestly more effective than narrowband UVB (85% vs. an unspecified but lower reduction), though both treatments produced statistically significant improvement.

Why Narrowband UVB Is Often Preferred as First-Line

Despite PUVA's slight efficacy edge in some studies, narrowband UVB has become the more commonly recommended first-line phototherapy option for several practical reasons: no photosensitizing medication is required, meaning fewer associated side effects and no need for post-treatment eye and skin protection; it can be safely used in pregnant women, breastfeeding mothers, children, and people with liver or kidney dysfunction, none of which reliably apply to PUVA; and it appears to carry a lower long-term skin cancer risk than PUVA, which has more established long-term carcinogenicity data given its longer history of use.

When PUVA Remains the Better Choice

PUVA is often reserved as the treatment of choice specifically for patients who don't respond adequately to narrowband UVB, experience rapid relapse after narrowband UVB, or have more severe baseline disease, where the research suggests a genuine efficacy advantage. It's also specifically indicated for certain presentations, including pustular or erythrodermic psoriasis.

Effectiveness in Skin of Color

A 2025 meta-analysis focused on narrowband UVB in patients with skin of color found 70.5% achieved PASI-75, with all included studies showing statistically significant improvement — and no significant difference compared to PUVA in this population specifically, reinforcing narrowband UVB's role as an effective, accessible first-line option.

Frequently Asked Questions

Which is better, narrowband UVB or PUVA?

Neither is universally "better" — narrowband UVB is generally preferred first-line due to its safety and convenience advantages, while PUVA shows a genuine efficacy edge for more severe cases or those unresponsive to narrowband UVB.

How many phototherapy sessions are typically needed?

This varies by treatment type and individual response, but both typically require multiple sessions per week over several weeks to reach meaningful clearance — phototherapy is a gradual, cumulative treatment rather than a fast-acting one.

Next Steps

For a broader comparison of psoriasis treatment options and timelines, see our full article on treatment timelines.

This article is for general educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Phototherapy should always be administered under medical supervision.

Sources & References

• Narrowband UV-B Phototherapy vs Photochemotherapy in the Treatment of Chronic Plaque-Type Psoriasis. JAMA Dermatology. PubMed
• Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen PUVA for chronic plaque psoriasis. PubMed
• Narrowband-Ultraviolet B Phototherapy for Psoriasis Treatment in Skin of Color: A Systematic Review and Meta-Analysis. PMC12411661